Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap

Andrew Chan, Carlos Vila Silván

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Abstract

Effective symptomatic management of multiple sclerosis (MS) spasticity remains an unmet need for many patients. The second-line option nabiximols is the most widely investigated of the noninvasive antispasticity medications in this patient population. Clinical evidence accumulated with nabiximols since it was first approved in Europe in 2010 suggests that about 40% of initial responders (i.e., those with ≥20% improvement in their baseline 0-10 Numerical Rating Scale score) may expect to achieve clinically meaningful (≥30% Numerical Rating Scale response) and durable symptomatic improvement in MS spasticity. During 10 years' routine use of nabiximols, no new safety signals have emerged. Nabiximols-associated improvement in MS spasticity-related symptoms such as pain and sleep disruption suggests a need to track possible therapeutic effects beyond muscle tone control.

Original languageEnglish
Pages (from-to)141-154
Number of pages14
JournalNeurodegenerative Disease Management
Volume12
Issue number3
DOIs
StatePublished - Jun 2022
Externally publishedYes

Keywords

  • Multiple sclerosis spasticity
  • Nabiximols
  • Real-world evidence
  • Spasticity-plus syndrome

Fingerprint

Dive into the research topics of 'Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap'. Together they form a unique fingerprint.

Cite this